Jordi Barretina
Affiliations: | Dana-Farber Cancer Institute, Boston, MA, United States |
Google:
"Jordi Barretina"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Tiedt R, King FJ, Stamm C, et al. (2023) Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors. Cell Reports. 42: 112297 |
Ansari-Pour N, Zheng Y, Yoshimatsu TF, et al. (2021) Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes. Nature Communications. 12: 6946 |
Raoof S, Mulford IJ, Frisco-Cabanos H, et al. (2019) Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer. Oncogene |
Wang S, Pitt JJ, Zheng Y, et al. (2019) Germline variants and somatic mutation signatures of breast cancer across populations of African and European ancestry in the US and Nigeria. International Journal of Cancer |
Li H, Ning S, Ghandi M, et al. (2019) The landscape of cancer cell line metabolism. Nature Medicine. 25: 850-860 |
Ghandi M, Huang FW, Jané-Valbuena J, et al. (2019) Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature |
Barretina J, Caponigro G, Stransky N, et al. (2018) Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature |
Pitt JJ, Riester M, Zheng Y, et al. (2018) Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features. Nature Communications. 9: 4181 |
Jia Y, Juarez J, Li J, et al. (2016) EGF816 exerts anticancer effects in non-small cell lung cancer by irreversibly and selectively targeting primary and acquired activating mutations in the EGF receptor. Cancer Research |
Bellmunt J, Selvarajah S, Rodig S, et al. (2014) Identification of ALK gene alterations in urothelial carcinoma. Plos One. 9: e103325 |